ClinVar Genomic variation as it relates to human health
NM_000516.7(GNAS):c.565_568del (p.Asp189fs)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
Pathogenic(10); Uncertain significance(1)
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000516.7(GNAS):c.565_568del (p.Asp189fs)
Variation ID: 15938 Accession: VCV000015938.22
- Type and length
-
Deletion, 4 bp
- Location
-
Cytogenetic: 20q13.32 20: 58909194-58909197 (GRCh38) [ NCBI UCSC ] 20: 57484249-57484252 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Sep 30, 2017 Oct 8, 2024 Apr 4, 2024 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000516.7:c.563_566del MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NM_000516.7:c.565_568del MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000507.1:p.Asp189fs frameshift NM_016592.5:c.*471_*474del MANE Plus Clinical Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
3 prime UTR NM_080425.4:c.2494_2497del MANE Plus Clinical Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_536350.2:p.Asp832fs frameshift NM_000516.4:c.565_568delGACT NM_001077488.5:c.568_571del NP_001070956.1:p.Asp190fs frameshift NM_001077489.4:c.520_523del NP_001070957.1:p.Asp174fs frameshift NM_001077490.3:c.*426_*429del 3 prime UTR NM_001309840.2:c.388_391del NP_001296769.1:p.Asp130fs frameshift NM_001309861.2:c.388_391del NP_001296790.1:p.Asp130fs frameshift NM_080426.4:c.523_526del NP_536351.1:p.Asp175fs frameshift NC_000020.11:g.58909196_58909199del NC_000020.10:g.57484251_57484254del NG_016194.2:g.74457_74460del - Protein change
- D130fs, D174fs, D175fs, D189fs, D190fs, D832fs
- Other names
-
D189MfsX14
- Canonical SPDI
- NC_000020.11:58909193:CTGACT:CT
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
- -
- Links
- Comment on variant
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
GNAS | Sufficient evidence for dosage pathogenicity | No evidence available |
GRCh38 GRCh37 |
939 | 1095 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (2) |
criteria provided, single submitter
|
Oct 1, 2019 | RCV000017300.37 | |
Pathogenic (2) |
no assertion criteria provided
|
Jul 15, 2008 | RCV000017301.40 | |
Pathogenic (1) |
no assertion criteria provided
|
Jul 15, 2008 | RCV000017302.39 | |
Pathogenic (1) |
criteria provided, single submitter
|
Dec 20, 2017 | RCV000678707.9 | |
Conflicting interpretations of pathogenicity (2) |
criteria provided, conflicting classifications
|
Apr 4, 2024 | RCV001196108.12 | |
Pathogenic (1) |
criteria provided, single submitter
|
Jun 1, 2020 | RCV001731307.9 | |
Pathogenic (2) |
criteria provided, multiple submitters, no conflicts
|
Dec 27, 2023 | RCV001851884.14 | |
Pathogenic (1) |
criteria provided, single submitter
|
Apr 15, 2022 | RCV003227604.8 | |
Pathogenic (1) |
criteria provided, single submitter
|
Apr 25, 2022 | RCV002496387.8 | |
Pathogenic (1) |
criteria provided, single submitter
|
Jan 25, 2023 | RCV003162254.9 | |
GNAS-related disorder
|
Pathogenic (1) |
no assertion criteria provided
|
Aug 29, 2024 | RCV004532373.2 |
Disorders of GNAS Inactivation
|
Pathogenic (1) |
criteria provided, single submitter
|
Aug 4, 2023 | RCV003389234.1 |
click to load more click to collapse |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Dec 20, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: unknown
Allele origin:
germline
|
Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital
Accession: SCV000804871.1
First in ClinVar: Sep 14, 2018 Last updated: Sep 14, 2018 |
|
|
Pathogenic
(Oct 01, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Pseudohypoparathyroidism type I A
Affected status: unknown
Allele origin:
germline
|
Johns Hopkins Genomics, Johns Hopkins University
Accession: SCV000992358.2
First in ClinVar: Sep 11, 2019 Last updated: Mar 07, 2020 |
|
|
Pathogenic
(Feb 24, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Pseudohypoparathyroidism type 1B
Affected status: yes
Allele origin:
unknown
|
Centre for Mendelian Genomics, University Medical Centre Ljubljana
Accession: SCV001366579.2
First in ClinVar: Jul 06, 2020 Last updated: Jul 06, 2020 |
Comment:
This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM1,PM2,PP5.
|
|
Pathogenic
(Apr 25, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Pseudohypoparathyroidism type I A
Progressive osseous heteroplasia McCune-Albright syndrome ACTH-independent macronodular adrenal hyperplasia 1 Pseudohypoparathyroidism type 1B Pseudohypoparathyroidism type 1C Pseudopseudohypoparathyroidism Pituitary adenoma 3, multiple types
Affected status: unknown
Allele origin:
unknown
|
Fulgent Genetics, Fulgent Genetics
Accession: SCV002806191.1
First in ClinVar: Dec 31, 2022 Last updated: Dec 31, 2022 |
|
|
Pathogenic
(Apr 06, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV002499789.2
First in ClinVar: Apr 23, 2022 Last updated: Mar 04, 2023 |
Comment:
Reported as a common pathogenic variant in association with disorders of GNAS inactivation (Haldeman-Englert et al., 2017); Published functional studies demonstrate a damaging effect (Weinstein … (more)
Reported as a common pathogenic variant in association with disorders of GNAS inactivation (Haldeman-Englert et al., 2017); Published functional studies demonstrate a damaging effect (Weinstein et al., 1992; Inta et al., 2014); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29059381, 29072892, 24481334, 21525160, 24626099, 18553568, 15711092, 11784876, 12024004, 9876352, 30729047, 1505964, 20427508, 31793173, 31886927) (less)
|
|
Pathogenic
(Apr 15, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Pseudohypoparathyroidism type I A
Pseudohypoparathyroidism type 1B Pseudohypoparathyroidism type 1C Pseudohypoparathyroidism type 1B Progressive osseous heteroplasia
Affected status: unknown
Allele origin:
germline
|
New York Genome Center
Accession: SCV003925361.1
First in ClinVar: May 20, 2023 Last updated: May 20, 2023 |
Comment:
The c.565_568del p.(Asp189MetfsTer14) variant identified in the GNAS gene has previously been reported in many individuals with Progressive osseous heteroplasia as well as pseudohypoparathyroidism type … (more)
The c.565_568del p.(Asp189MetfsTer14) variant identified in the GNAS gene has previously been reported in many individuals with Progressive osseous heteroplasia as well as pseudohypoparathyroidism type 1a [PMID: 23796510, 11784876, 20427508, 30729047] and it has been deposited in ClinVar [ClinVarID: 15938] as Pathogenic. The c.565_568del variant is observed in 1 allele (0.0003% MAF with 0 homozygotes) in population databases (gnomAD v2.1.1 and v3.1.2,TOPMed Freeze 8), suggesting it is not a common benign variant in the populations represented in those databases. The c.565_568del p.(Asp189MetfsTer14) variant in the GNAS gene is located in exon 7 of this 13-exon gene, predicted to incorporate a premature termination codon (p.(Asp189MetfsTer14)), and is expected to resultin loss-of-function either through protein truncation or nonsense-mediated mRNA decay. Multiple loss-of-function variants that are downstream to the c.565_568del variant have been reported in the literature [PMID: 20427508, 31886927] in individuals with Progressive osseous heteroplasia or pseudohypoparathyroidism type 1a. Based on available evidence this c.565_568del p.(Asp189MetfsTer14) variant identified in GNAS is classified as Pathogenic. (less)
Clinical Features:
Hyperlipidemia (present) , Type 2 diabetes mellitus (present)
Secondary finding: no
|
|
Pathogenic
(Aug 04, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Disorders of GNAS Inactivation
Affected status: unknown
Allele origin:
unknown
|
Illumina Laboratory Services, Illumina
Accession: SCV004101287.1
First in ClinVar: Nov 11, 2023 Last updated: Nov 11, 2023 |
Comment:
The GNAS c.565_568del (p.Asp189MetfsTer14) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss … (more)
The GNAS c.565_568del (p.Asp189MetfsTer14) variant causes a shift in the protein reading frame that is predicted to result in premature termination of the protein. Loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay is expected. This variant has been identified in multiple individuals with phenotypes consistent with disorders of GNAS inactivation (PMID: 23796510; 35296306). The c.565_568del variant is not observed in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Functional studies conducted in patient cells demonstrated that this variant leads to reduced mRNA expression (PMID: 1505964). This variant has been classified as pathogenic by multiple submitters in ClinVar. Based on the available evidence, the c.565_568del variant is classified as pathogenic for disorders of GNAS inactivation. (less)
|
|
Pathogenic
(Dec 27, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV002232612.3
First in ClinVar: Mar 28, 2022 Last updated: Feb 14, 2024 |
Comment:
This sequence change creates a premature translational stop signal (p.Asp189Metfs*14) in the GNAS gene. It is expected to result in an absent or disrupted protein … (more)
This sequence change creates a premature translational stop signal (p.Asp189Metfs*14) in the GNAS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNAS are known to be pathogenic (PMID: 11784876, 23281139, 23796510, 25802881). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with GNAS-related conditions (PMID: 20427508). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 15938). For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Uncertain significance
(Apr 04, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Pseudohypoparathyroidism type 1B
Affected status: unknown
Allele origin:
germline
|
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center
Accession: SCV004809832.1
First in ClinVar: Apr 15, 2024 Last updated: Apr 15, 2024 |
|
|
Pathogenic
(Jan 25, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Inborn genetic diseases
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV003887548.2
First in ClinVar: Apr 15, 2023 Last updated: May 01, 2024 |
Comment:
The c.565_568delGACT (p.D189Mfs*14) alteration, located in exon 7 (coding exon 7) of the GNAS gene, consists of a deletion of 4 nucleotides from position 565 … (more)
The c.565_568delGACT (p.D189Mfs*14) alteration, located in exon 7 (coding exon 7) of the GNAS gene, consists of a deletion of 4 nucleotides from position 565 to 568, causing a translational frameshift with a predicted alternate stop codon after 14 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay._x000D_ _x000D_ Based on the available evidence, the GNAS c.565_568delGACT (p.D189Mfs*14) alteration is classified as pathogenic for pseudohypoparathyroidism and pseudopseudohypoparathyroidism; however, it is unlikely to be causative of McCune-Albright syndrome. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This alteration was detected in the heterozygous state in multiple individuals with pseudohypoparathyroidism or pseudopseudohypoparathyroidism (Chang, 2022; Goode, 2022; Itoh, 2022; Stembridge, 2021; Mendes, 2021; Ozaki, 2021; Crane, 2020; Snanoudj, 2020; Del Monte, 2019; Miyakawa, 2019; Salemi, 2018; Inta, 2014; Schrander, 2014; Elli, 2013; Lebrun, 2010; Adegbite, 2008; Shore, 2002; Weinstein, 1992) Based on the available evidence, this alteration is classified as pathogenic. (less)
|
|
Pathogenic
(Jun 01, 2020)
|
criteria provided, single submitter
Method: research
|
Pseudohypoparathyroidism type I A
Affected status: yes
Allele origin:
de novo
|
Genetics of Obesity Study, University of Cambridge
Accession: SCV001573812.1
First in ClinVar: Oct 30, 2021 Last updated: Oct 30, 2021 |
|
|
Pathogenic
(Jul 15, 2008)
|
no assertion criteria provided
Method: literature only
|
PSEUDOHYPOPARATHYROIDISM, TYPE IA
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000037572.5
First in ClinVar: Apr 04, 2013 Last updated: Sep 30, 2017 |
Comment on evidence:
In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in … (more)
In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in a frameshift and premature stop codon. Analysis of lymphocyte RNA by reverse transcription-PCR and direct sequencing showed that the GNAS1 allele bearing the mutation was not expressed as mRNA. Consistent with this, Northern blot analysis revealed an approximately 50% deficiency in steady-state levels of GNAS1 mRNA. Ahmed et al. (1998) identified this deletion mutation in 2 unrelated families with PHP Ia. Shore et al. (2002) provided direct evidence that the 4-bp deletion can cause either progressive osseous heteroplasia (POH; 166350) or Albright hereditary osteodystrophy without hormone resistance (PPHP; 612463) in the same family. Five sisters with POH had inherited this mutation from the father in whom the mutation was nonpenetrant. Three offspring of these sisters had AHO, including traces of subcutaneous ossification. Shore et al. (2002) suggested that POH requires paternal inheritance of a GNAS1 mutation, whereas hormone resistance is more likely to occur when the genetic defect is maternally inherited. Ahmed et al. (2002) cautioned against a premature conclusion that POH may require paternal inheritance. In a family reported by Ahmed et al. (1998), the 4-bp deletion was found in a brother and sister and in their mother but not in their father. Aside from brachymetacarpia and short stature, the mother did not have features of AHO. The daughter had typical features of AHO and hormone resistant PHP1A; in contrast, her brother presented in the first year of life with ossification of subcutaneous tissue that was followed by progressive, generalized heterotopic ossification of skeletal muscle, without any clear evidence of hormone resistance. These cases exemplified the wide phenotypic heterogeneity in persons with mutations in GNAS1, even within 1 family. Bastepe and Juppner (2002) suggested that, like some patients who have either PHP type Ia or PHP type Ib, the son described by Ahmed et al. (1998) may have developed resistance to parathyroid hormone later in life or not at all. Given that the patient's sister and mother had PHP type Ia and PPHP, respectively, POH resulting from maternally inherited GNAS1 mutations may actually represent an incomplete form of PHP type Ia. Bastepe and Juppner (2002) suggested that the underlying mechanism for this form of POH may be distinct from that described by Shore et al. (2002), which appears to result only from paternally inherited GNAS1 mutations. Adegbite et al. (2008) identified heterozygosity for the 565delCTGA mutation in the GNAS gene in 13 POH cases (10 familial cases among 3 different families, and 3 individual spontaneous cases). The mutation resulted in variable severity and pleiotropy, both in family members and in unrelated sporadic cases. (less)
|
|
Pathogenic
(Jul 15, 2008)
|
no assertion criteria provided
Method: literature only
|
OSSEOUS HETEROPLASIA, PROGRESSIVE
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000037573.5
First in ClinVar: Apr 04, 2013 Last updated: Sep 30, 2017 |
Comment on evidence:
In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in … (more)
In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in a frameshift and premature stop codon. Analysis of lymphocyte RNA by reverse transcription-PCR and direct sequencing showed that the GNAS1 allele bearing the mutation was not expressed as mRNA. Consistent with this, Northern blot analysis revealed an approximately 50% deficiency in steady-state levels of GNAS1 mRNA. Ahmed et al. (1998) identified this deletion mutation in 2 unrelated families with PHP Ia. Shore et al. (2002) provided direct evidence that the 4-bp deletion can cause either progressive osseous heteroplasia (POH; 166350) or Albright hereditary osteodystrophy without hormone resistance (PPHP; 612463) in the same family. Five sisters with POH had inherited this mutation from the father in whom the mutation was nonpenetrant. Three offspring of these sisters had AHO, including traces of subcutaneous ossification. Shore et al. (2002) suggested that POH requires paternal inheritance of a GNAS1 mutation, whereas hormone resistance is more likely to occur when the genetic defect is maternally inherited. Ahmed et al. (2002) cautioned against a premature conclusion that POH may require paternal inheritance. In a family reported by Ahmed et al. (1998), the 4-bp deletion was found in a brother and sister and in their mother but not in their father. Aside from brachymetacarpia and short stature, the mother did not have features of AHO. The daughter had typical features of AHO and hormone resistant PHP1A; in contrast, her brother presented in the first year of life with ossification of subcutaneous tissue that was followed by progressive, generalized heterotopic ossification of skeletal muscle, without any clear evidence of hormone resistance. These cases exemplified the wide phenotypic heterogeneity in persons with mutations in GNAS1, even within 1 family. Bastepe and Juppner (2002) suggested that, like some patients who have either PHP type Ia or PHP type Ib, the son described by Ahmed et al. (1998) may have developed resistance to parathyroid hormone later in life or not at all. Given that the patient's sister and mother had PHP type Ia and PPHP, respectively, POH resulting from maternally inherited GNAS1 mutations may actually represent an incomplete form of PHP type Ia. Bastepe and Juppner (2002) suggested that the underlying mechanism for this form of POH may be distinct from that described by Shore et al. (2002), which appears to result only from paternally inherited GNAS1 mutations. Adegbite et al. (2008) identified heterozygosity for the 565delCTGA mutation in the GNAS gene in 13 POH cases (10 familial cases among 3 different families, and 3 individual spontaneous cases). The mutation resulted in variable severity and pleiotropy, both in family members and in unrelated sporadic cases. (less)
|
|
Pathogenic
(Jul 15, 2008)
|
no assertion criteria provided
Method: literature only
|
PSEUDOPSEUDOHYPOPARATHYROIDISM
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000037574.5
First in ClinVar: Apr 04, 2013 Last updated: Sep 30, 2017 |
Comment on evidence:
In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in … (more)
In a patient with PHP1A (103580), Weinstein et al. (1992) identified a heterozygous 4-bp deletion (565delCTGA) in exon 7 of the GNAS1 gene, resulting in a frameshift and premature stop codon. Analysis of lymphocyte RNA by reverse transcription-PCR and direct sequencing showed that the GNAS1 allele bearing the mutation was not expressed as mRNA. Consistent with this, Northern blot analysis revealed an approximately 50% deficiency in steady-state levels of GNAS1 mRNA. Ahmed et al. (1998) identified this deletion mutation in 2 unrelated families with PHP Ia. Shore et al. (2002) provided direct evidence that the 4-bp deletion can cause either progressive osseous heteroplasia (POH; 166350) or Albright hereditary osteodystrophy without hormone resistance (PPHP; 612463) in the same family. Five sisters with POH had inherited this mutation from the father in whom the mutation was nonpenetrant. Three offspring of these sisters had AHO, including traces of subcutaneous ossification. Shore et al. (2002) suggested that POH requires paternal inheritance of a GNAS1 mutation, whereas hormone resistance is more likely to occur when the genetic defect is maternally inherited. Ahmed et al. (2002) cautioned against a premature conclusion that POH may require paternal inheritance. In a family reported by Ahmed et al. (1998), the 4-bp deletion was found in a brother and sister and in their mother but not in their father. Aside from brachymetacarpia and short stature, the mother did not have features of AHO. The daughter had typical features of AHO and hormone resistant PHP1A; in contrast, her brother presented in the first year of life with ossification of subcutaneous tissue that was followed by progressive, generalized heterotopic ossification of skeletal muscle, without any clear evidence of hormone resistance. These cases exemplified the wide phenotypic heterogeneity in persons with mutations in GNAS1, even within 1 family. Bastepe and Juppner (2002) suggested that, like some patients who have either PHP type Ia or PHP type Ib, the son described by Ahmed et al. (1998) may have developed resistance to parathyroid hormone later in life or not at all. Given that the patient's sister and mother had PHP type Ia and PPHP, respectively, POH resulting from maternally inherited GNAS1 mutations may actually represent an incomplete form of PHP type Ia. Bastepe and Juppner (2002) suggested that the underlying mechanism for this form of POH may be distinct from that described by Shore et al. (2002), which appears to result only from paternally inherited GNAS1 mutations. Adegbite et al. (2008) identified heterozygosity for the 565delCTGA mutation in the GNAS gene in 13 POH cases (10 familial cases among 3 different families, and 3 individual spontaneous cases). The mutation resulted in variable severity and pleiotropy, both in family members and in unrelated sporadic cases. (less)
|
|
Pathogenic
(Aug 29, 2024)
|
no assertion criteria provided
Method: clinical testing
|
GNAS-related condition
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV004749516.2
First in ClinVar: Mar 16, 2024 Last updated: Oct 08, 2024 |
Comment:
The GNAS c.565_568delGACT variant is predicted to result in a frameshift and premature protein termination (p.Asp189Metfs*14). This variant has been reported in many unrelated individuals … (more)
The GNAS c.565_568delGACT variant is predicted to result in a frameshift and premature protein termination (p.Asp189Metfs*14). This variant has been reported in many unrelated individuals with either progressive osseous heteroplasia (POH) or pseudohypoparathyroidism type 1a (PHP1a) (Lebrun et al. 2010. PubMed ID: 20427508; Salemi et al. 2018. PubMed ID: 29059381; Inta et al. 2014. PubMed ID: 24481334). In several of these patients this variant was found to occur de novo (Lebrun et al. 2010. PubMed ID: 20427508; Crane et al. 2019. PubMed ID: 31793173). This variant has not been reported in a large population database, indicating this variant is rare. Frameshift variants in GNAS are expected to be pathogenic. This variant is interpreted as pathogenic. (less)
|
|
not provided
(-)
|
no classification provided
Method: literature only
|
Progressive osseous heteroplasia
Affected status: unknown
Allele origin:
germline
|
GeneReviews
Accession: SCV000611857.2
First in ClinVar: Sep 30, 2017 Last updated: Oct 01, 2022 |
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1a. | Itoh M | Bone reports | 2022 | PMID: 35497370 |
Diagnostic and Prognostic Implications of GNAS Inactivation in Sonic Hedgehog-Activated Medulloblastoma: Case Report with Comprehensive Molecular Profiling and Review of Literature. | Goode E | JCO precision oncology | 2022 | PMID: 35357904 |
Evaluating the variety of GNAS inactivation disorders and their clinical manifestations in 11 Chinese children. | Chang G | BMC endocrine disorders | 2022 | PMID: 35296306 |
Obesity-Associated GNAS Mutations and the Melanocortin Pathway. | Mendes de Oliveira E | The New England journal of medicine | 2021 | PMID: 34614324 |
Infantile-onset osteoma cutis with pseudopseudohypoparathyroidism. | Stembridge N | Clinical and experimental dermatology | 2021 | PMID: 34418133 |
Mild progressive osseous heteroplasia overlap syndrome with PTH and TSH resistance appearing during adolescence and not early childhood. | Ozaki K | Endocrine | 2021 | PMID: 34254228 |
Maternal Transmission Ratio Distortion of GNAS Loss-of-Function Mutations. | Snanoudj S | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2020 | PMID: 31886927 |
A case report of a novel germline GNAS mutation in sonic hedgehog activated medulloblastoma. | Crane JN | Pediatric blood & cancer | 2020 | PMID: 31793173 |
Unrecognized Pseudohypoparathyroidism Type 1A as a Cause of Hypocalcemia and Seizures in a 64-Year-Old Woman. | Del Monte P | Case reports in endocrinology | 2019 | PMID: 30729047 |
Language delay and developmental catch-up would be a clinical feature of pseudohypoparathyroidism type 1A during childhood. | Miyakawa Y | Endocrine journal | 2019 | PMID: 30674755 |
Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. | Salemi P | The Journal of clinical endocrinology and metabolism | 2018 | PMID: 29059381 |
A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene. | Thiele S | Molecular genetics & genomic medicine | 2015 | PMID: 25802881 |
GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. | Lemos MC | Human mutation | 2015 | PMID: 25219572 |
Endochondral ossification in a case of progressive osseous heteroplasia in a young female child. | Schrander DE | Journal of pediatric orthopedics. Part B | 2014 | PMID: 24626099 |
Guanine nucleotide-binding protein α subunit hypofunction in children with short stature and disproportionate shortening of the 4th and 5th metacarpals. | Inta IM | Hormone research in paediatrics | 2014 | PMID: 24481334 |
Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series. | Elli FM | Bone | 2013 | PMID: 23796510 |
Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations. | Elli FM | Human mutation | 2013 | PMID: 23281139 |
Progressive osseous heteroplasia: a model for the imprinting effects of GNAS inactivating mutations in humans. | Lebrun M | The Journal of clinical endocrinology and metabolism | 2010 | PMID: 20427508 |
Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. | Adegbite NS | American journal of medical genetics. Part A | 2008 | PMID: 18553568 |
GNAS locus and pseudohypoparathyroidism. | Bastepe M | Hormone research | 2005 | PMID: 15711092 |
GNAS1 mutations and progressive osseous heteroplasia. | Ahmed SF | The New England journal of medicine | 2002 | PMID: 12024004 |
Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. | Shore EM | The New England journal of medicine | 2002 | PMID: 11784876 |
GNAS1 mutational analysis in pseudohypoparathyroidism. | Ahmed SF | Clinical endocrinology | 1998 | PMID: 9876352 |
A heterozygous 4-bp deletion mutation in the Gs alpha gene (GNAS1) in a patient with Albright hereditary osteodystrophy. | Weinstein LS | Genomics | 1992 | PMID: 1505964 |
click to load more click to collapse |
Text-mined citations for rs587776829 ...
HelpRecord last updated Nov 10, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.
NCBI staff reviewed the sequence information reported in PubMed 1505964 Fig. 2 to determine the location of this allele on the current reference sequence.